Update on emerging drugs for sarcopenia - age-related muscle wasting
Gordon S Lynch
EXPERT OPINION ON EMERGING DRUGS | TAYLOR & FRANCIS LTD | Published : 2008
UNLABELLED: Sarcopenia - the progressive loss of muscle mass with advancing age is characterised by a deterioration of muscle quantity and quality leading to a gradual slowing of movement and a decline in strength and power. Sarcopenia is a highly significant public health problem. Frail elders often require assistance for accomplishing even basic tasks of independent living, and they are also at increased risk of serious injury from sudden falls and subsequent fractures. Since these age-related changes are largely attributed to the complex interaction of factors affecting neuromuscular transmission, muscle architecture, fibre composition, excitation-contraction coupling, and metabolism, the..View full abstract
Awarded by Australian Research Council Discovery
Awarded by National Health and Medical Research Council of Australia
Awarded by Muscular Dystrophy Association (USA)
The author is grateful for research grant support from the Australian Research Council Discovery-Project funding scheme (DP0665071, DP0772781), National Health and Medical Research Council of Australia (454561, 509313, 566818, 566820), Muscular Dystrophy Association (USA, 4167), Association Francaise contre les Myopathies, Pfizer, Inc. (USA), E Hoffmann-La Roche Ltd. (Switzerland) and Merck & Co., Inc. (USA).